AMA Not Required to Disclose Sources of GlaxoSmithKline Article

The American Medical Association won’t have to disclose the names of its peer reviewers, including a government official, that were involved in a 2020 decision to soften an article in its medical journal linking GlaxoSmithKline Plc’s heartburn drug, Zantac, to cancer.

An Illinois appellate court held Friday that the information is protected by state reporter-protection laws and not essential to the public interests.

The Journal of the American Medical Association, or JAMA, was scheduled to publish an article asserting Zantac, a blockbuster drug for Glaxo, was a carcinogen. The day before the manuscript was scheduled to be published, the AMA ...